| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/05/2004 | US20040023971 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023954 Hypotensive drugs Bimatoprost, Latanaprost, Unoprostone, Travoprost and prostaglandin H2 1-ethanolamide or of structurally closely related analogs, are pro-drugs which hydrolyze under physiological conditions to provide |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023947 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023923 Beta -Glucan which is cold-water soluble and is capable of forming a gel. The solubility is greater than 2% by weight in water at a temperature below approximately 50 degrees C. A process for preparing the beta -glucan by recovering the |
| 02/05/2004 | US20040023893 Coumarin derivatives for treatment of vascular disorders, skin disorders or allergies |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023881 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023872 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/05/2004 | US20040023869 Interleukin-1 inhibitors in the treatment of diseases |
| 02/05/2004 | US20040023862 Newly identified uses of BRS3 polypeptides and polynucleotides encoding such polypeptides, to their use in therapy of ischemia, of neurodegenerative diseases, of memory and attention disorders, and in identifying compounds which may be |
| 02/05/2004 | US20040023859 New melanocortin receptor ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040023840 Combination of organic compounds |
| 02/05/2004 | US20040023337 IL-13 mutein proteins, antibodies, compositions, methods and uses |
| 02/05/2004 | US20040023278 Sialoadhesin family member-2 (SAF-2) |
| 02/05/2004 | US20040022883 Persea americana var. drymifolia leaves (avocado) |
| 02/05/2004 | US20040022879 Platelet Activating Factor Inhibitor and an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity; especially useful for treating asthma in children. |
| 02/05/2004 | US20040022877 Soy protein readily dissolves in orange juice and does not unacceptably negatively impact sensory, mouth feel and viscosity; lowers cholesterol levels and blood pressure readings |
| 02/05/2004 | US20040022806 Oral preparation containing seaweed for reduction of plaque and calculus |
| 02/05/2004 | US20040022801 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/05/2004 | US20040022791 Use of the heavy chain of an antibody, of a functional derivative, or of a fragment thereof, comprising a CDR3 region for jointly inhibiting fibrinogen binding to platelets and vitronectin binding to endothelial cells |
| 02/05/2004 | US20040022778 For therapy and prophylaxis of cardiovascular disease, strokes and myocardial infarction |
| 02/05/2004 | US20040022777 Fragments and antagonists of heat shock protein 60 |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | CA2495167A1 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 02/05/2004 | CA2494668A1 Chemical compounds |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493913A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | CA2493790A1 Food improving blood flow |
| 02/05/2004 | CA2493761A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493639A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | CA2493172A1 Method of treating tumors |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2493128A1 Crystalline .beta.2 adrenergic receptor agonist |
| 02/05/2004 | CA2493076A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | CA2492858A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/04/2004 | EP1386921A1 Intermediates |
| 02/04/2004 | EP1386917A1 Intermediates |
| 02/04/2004 | EP1386912A1 Cyclic amidine derivative |
| 02/04/2004 | EP1386909A1 Cyclopropane amines |
| 02/04/2004 | EP1386908A1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 02/04/2004 | EP1386905A1 Stable solution of reduced coenzyme q |
| 02/04/2004 | EP1386624A1 Coated vascular devices |
| 02/04/2004 | EP1386606A1 Stable high− concentration injection containing pyrazolone derivative |
| 02/04/2004 | EP1386279A2 Method for inhibiting metap2 |
| 02/04/2004 | EP1386166A2 Anti-epileptogenic agents |
| 02/04/2004 | EP1386165A2 Inflammatory markers for detection and prevention of diabetes mellitus |
| 02/04/2004 | EP1385980A2 Yeast strains autonomously producing steroids |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385953A2 Proteins and nucleic acids encoding same |
| 02/04/2004 | EP1385937A1 Delivery of polynucleotide agents to the central nervous sysstem |
| 02/04/2004 | EP1385934A2 Pufa polyketide synthase systems and uses thereof |
| 02/04/2004 | EP1385883A2 Transmembrane proteins |
| 02/04/2004 | EP1385864A1 Vascular endothelial growth factor 2 |
| 02/04/2004 | EP1385858A1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof |
| 02/04/2004 | EP1385856A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 02/04/2004 | EP1385851A1 New process for the preparation of oxabispidines |
| 02/04/2004 | EP1385850A1 New process for the preparation of oxabispidines |
| 02/04/2004 | EP1385848A2 Phtalazinones derivatives useful as pde4/7 inhibitors |
| 02/04/2004 | EP1385845A1 N-aroyl cyclic amines |
| 02/04/2004 | EP1385843A1 Arylindenopyridines with pde inhibiting activity |
| 02/04/2004 | EP1385841A1 Sulfonamides |
| 02/04/2004 | EP1385840A1 Sulfonamides |
| 02/04/2004 | EP1385839A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/04/2004 | EP1385836A2 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/04/2004 | EP1385835A1 Benzoxazinone derivatives for use in the treatment of angiogenesis |
| 02/04/2004 | EP1385830A1 Sulfonamides |
| 02/04/2004 | EP1385825A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives |
| 02/04/2004 | EP1385824A2 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| 02/04/2004 | EP1385822A1 Aminopyrrolidine sulfonamides as serine protease inhibitors |
| 02/04/2004 | EP1385820A1 Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof |
| 02/04/2004 | EP1385818A2 Biurethane derivatives |
| 02/04/2004 | EP1385578A1 Utilization of rutins and aescins in the treatment of circulatory disturbances of the ear |
| 02/04/2004 | EP1385548A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/04/2004 | EP1385536A2 Preparations containing a combination of vitamin e and afamin |
| 02/04/2004 | EP1385535A2 Modified fvii in treatment of ards |
| 02/04/2004 | EP1385524A1 Pyrazolopyrimidines as therapeutic agents |
| 02/04/2004 | EP1385523A2 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| 02/04/2004 | EP1385521A2 Pharmaceutical composition containing pde v inhibitors and surfactants |
| 02/04/2004 | EP1385518A1 Benzimidazolone compounds |
| 02/04/2004 | EP1385514A1 Spiroindene and spiroindane compounds |
| 02/04/2004 | EP1385509A1 Method of treatment |
| 02/04/2004 | EP1385508A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/04/2004 | EP1385507A1 Sulfonamides |
| 02/04/2004 | EP1385501A2 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| 02/04/2004 | EP1385500A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation |
| 02/04/2004 | EP1385499A1 Method for improving the well-being of poultry by in-ovo injection of carnitine |
| 02/04/2004 | EP1385496A2 Use of compositions for treating rosacea |
| 02/04/2004 | EP1385495A2 Sulfonamides |
| 02/04/2004 | EP1385493A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties |
| 02/04/2004 | EP1296947B1 $g(A) CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT |
| 02/04/2004 | EP1203585A4 Anti-ischemic agent |
| 02/04/2004 | EP1115697B1 Unsaturated hydroximic acid derivatives as parp inhibitors |